報價延遲最少15分鐘:2024/11/10 19:12 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
91.36 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.86/0.66
|
|
企業價值
9.58B
|
| 資產負債 |
|
每股賬面淨值
10.83
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
462.18M
|
|
每股收益
3.96
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/10 19:12 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that addressneeds in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. |